Table 1.
Protocols | |||||
---|---|---|---|---|---|
Period | fRPP | scRPP | fRPP + E | scRPP + E | |
UF (ml min−1) | C1 | 0.42 ± 0.06§ | 0.30 ± 0.07 | 0.98 ± 0.22* | 0.64 ± 0.13 †‡ |
C2 | 0.50 ± 0.10§ | 0.30 ± 0.05 | 0.81 ± 0.12* | 0.59 ± 0.10‡ | |
C3 | 0.41 ± 0.08 | 0.30 ± 0.08 | 0.59 ± 0.12 | 0.50 ± 0.08 | |
I1 | 0.89 ± 0.12§ | 0.73 ± 0.14§ | 1.53 ± 0.23§* | 1.83 ± 0.31§ | |
I2 | 2.21 ± 0.10§ | 1.49 ± 0.25§* | 2.47 ± 0.32§ | 2.27 ± 0.36§‡ | |
I3 | 2.96 ± 0.25§ | 2.14 ± 0.27§* | 3.00 ± 0.26§ | 2.71 ± 0.22§ | |
I4 | 3.15 ± 0.17§ | 2.75 ± 0.18§ | 2.85 ± 0.28§ | 3.05 ± 0.36§ | |
I5 | 3.56 ± 0.21§ | 2.69 ± 0.32§* | 2.81 ± 0.31§ | 3.11 ± 0.28§ | |
P1 | 2.44 ± 0.18§ | 2.40 ± 0.31§ | 2.52 ± 0.15§ | 2.53 ± 0.23§ | |
P2 | 1.56 ± 0.27§ | 1.67 ± 0.29§ | 1.74 ± 0.18§ | 1.79 ± 0.31§ | |
UOsmol (mosmol kg−1) | C1 | 508 ± 56 | 620 ± 73 | 357 ± 79* | 459 ± 52‡ |
C2 | 486 ± 54 | 646 ± 59* | 396 ± 78 | 492 ± 46 | |
C3 | 504 ± 60 | 645 ± 74* | 460 ± 40 | 477 ± 39 | |
I1 | 428 ± 44 | 605 ± 77* | 334 ± 26 | 356 ± 26§ | |
I2 | 297 ± 23§ | 376 ± 62§ | 262 ± 38§ | 302 ± 16§ | |
I3 | 250 ± 13§ | 313 ± 17§ | 267 ± 28§ | 293 ± 27§ | |
I4 | 256 ± 20§ | 281 ± 21§ | 302 ± 40§ | 347 ± 29§ | |
I5 | 294 ± 16§ | 324 ± 13§ | 306 ± 17§ | 304 ± 25§ | |
P1 | 336 ± 18§ | 360 ± 18§ | 358 ± 21 | 332 ± 17§ | |
P2 | 443 ± 40 | 420 ± 23§ | 401 ± 31 | 405 ± 26 |
Values are mean ±s.e.m. of 9 dogs studied in 4 protocols during 3 control periods (C1–C3), 5 periods with Na+ loading by i.v. infusion (I1–I5) and 2 postinfusion periods (P1, P2). For protocols see Methods. Significant differences obtained by GLM ANOVA for repeated measurements + Duncan's multiple comparison test:
significant versus fRPP
significant versus fRPP + E
significant versus scRPP;
significant change versus control periods within the respective protocol.